Odatron

Quick links to important sections

Odatron

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Odatron

What is Odatron?

Odatron is a medication that belongs to a class of drugs known as serotonin 5-HT3 receptor antagonists. It is primarily used to manage and prevent nausea and vomiting that may occur as a result of specific medical treatments or surgical procedures.

Mechanism of Action

The active ingredient in Odatron works by blocking the action of serotonin, a natural substance in the body that can trigger the vomiting reflex. Serotonin is released in the small intestine and the brain's vomiting center during certain physiological stresses. By binding to specific 5-HT3 receptors, the medication interrupts the signaling process that leads to the sensation of nausea and the physical act of vomiting.

Clinical Applications

Odatron is commonly utilized in various clinical settings to improve patient comfort:

  • Medical Treatments: It is often administered to patients undergoing therapies that are known to cause significant gastrointestinal distress as a side effect.
  • Post-Operative Care: It is used in the recovery phase after surgery to address nausea that can result from anesthesia or the surgical procedure itself.

Therapeutic Goal

The primary objective of Odatron therapy is to minimize physical discomfort and assist patients in maintaining better hydration and nutritional intake during recovery or ongoing medical care. While it is effective at controlling the urge to vomit, it does not treat the underlying cause of the nausea, but rather manages the symptom through neurological and gastrointestinal receptor blockade.

What side effects are possible with Odatron?

Possible side effects and safety information

The official safety profile for Odatron (Ondansetron) organizes potential adverse reactions according to frequency and the body systems affected, following regulatory standards set by government health authorities.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped into categories based on reporting frequency in clinical data:

Classification Examples of Officially Listed Adverse Reactions
Very Common Headache
Common Constipation, Sensation of warmth or flushing, Local site reactions (with injectable forms)
Uncommon Hiccups, Seizures, Movement disorders, Bradycardia, Hypotension, Arrhythmias
Rare Transient visual disturbances, Hypersensitivity reactions, QTc prolongation
Very Rare Transient blindness (mostly following IV administration)

Serious Adverse Reactions and Safety Constraints

The label highlights specific safety concerns. Serious adverse reactions documented in regulatory sources include the potential for QT interval prolongation, which may lead to the life-threatening heart rhythm known as Torsade de Pointes, and the risk of Serotonin Syndrome, particularly when Odatron is used with other serotonergic medications.

Safety-related constraints specify that Odatron is strictly contraindicated for patients with a known hypersensitivity to the drug or in those receiving apomorphine. Specific consideration is also given to patients with severe hepatic impairment, where a lower total daily dose is recommended due to reduced drug clearance. Furthermore, the risk of QT prolongation is considered to be dose-dependent.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific manifestations and required actions in the event of an Odatron (Ondansetron) overdose. Documented presentations include transient visual disturbances, such as temporary blindness (amaurosis), severe constipation, and hypotension (low blood pressure).


Documented Severe Outcomes

Classification Detail Regulatory Description
Severity Classification Overdose carries the risk of life-threatening outcomes, notably QTc interval prolongation and subsequent severe ventricular arrhythmias, including Torsade de Pointes and cardiovascular collapse.
High-Risk Factors The risk of QTc prolongation is dose-dependent. Serotonin Syndrome is a potential severe outcome when Odatron is taken with other serotonergic medicines.

Required Emergency Actions

Management is primarily symptomatic and supportive, as no specific antidote is known. The official guidance from regulatory authorities mandates that continuous ECG monitoring is recommended in cases of overexposure due to the risk of cardiac toxicity. Individuals must seek immediate medical attention or urgent medical consultation for any suspected overdose or for symptoms such as an irregular heartbeat, significant dizziness, or fainting.

Therapeutic Uses of Odatron

Odatron (Ondansetron) provides supportive symptomatic relief by managing symptoms associated with acute or episodic changes of nausea and vomiting across key therapeutic domains. It is generally applied in contexts where symptoms may interfere with daily functioning and where short-term symptomatic assistance is needed, may provide support that helps ease the overall symptom burden.

This medication is commonly used to address conditions marked by increased physiological stress, including sickness associated with cancer chemotherapy, targeted radiation therapy, and Postoperative Nausea and Vomiting (PONV). It is also applied in addressing conditions involving episodic or fluctuating manifestations, such as severe sickness in pregnancy (Hyperemesis Gravidarum), Cyclic Vomiting Syndrome, and specific gastrointestinal distress like bowel urgency in IBS-D. Odatron may offer symptomatic relief that helps patients cope more steadily with difficult phases and supports general well-being during symptomatic periods. This medication may provide supportive relief during acute episodes, assisting with the symptomatic burden when nausea and vomiting become temporarily overwhelming.


Quick Fact: Support for Symptoms of Severe Nausea and Vomiting

Focus Symptom Category Patient Benefit
Primary Domain Sickness related to systemic imbalance Contributes to easing the overall symptom load.
Clinical Context Acute or unstable symptom patterns May assist with maintaining a sense of stability when symptoms are more noticeable.
Secondary Use Symptoms related to inflammatory/irritative states Provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official eligibility profile for Odatron (Ondansetron) is defined by strict regulatory rules regarding who is permitted to use the medicine and who is prohibited.

Category Eligibility Status
Contraindications Use is strictly prohibited in patients with known hypersensitivity to ondansetron or those receiving concomitant apomorphine. It is also contraindicated for patients with congenital Long QT Syndrome due to the risk of cardiac events.
Age Eligibility The medicine is approved for adults and adolescents. For children, it is approved for Chemotherapy-Induced Nausea and Vomiting (CINV) in those mathbfgeq 6 months and for Postoperative Nausea and Vomiting (PONV) in those mathbfgeq 1 month (injection form). Use is not established below these age thresholds.
Organ Function Patients with severe hepatic impairment must use Odatron under restricted conditions; the total daily dose must not exceed 8 mg. Use is generally allowed for patients with renal impairment, as no dosage adjustment is typically required.
Reproductive Status Use is generally not recommended during pregnancy, especially the first trimester, and breastfeeding is not recommended during treatment.

Caution is also required for patients with uncorrected electrolyte abnormalities or signs of intestinal obstruction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Odatron (Ondansetron), based strictly on regulatory prescribing information.

Formal Interaction Constraints

Classification Interacting Substance Regulatory Outcome
Contraindicated Apomorphine Risk of profound hypotension and loss of consciousness.
Risk Amplification Serotonergic Drugs (e.g., SSRIs, SNRIs) Associated with risk of Serotonin Syndrome.
Risk Amplification QT-prolonging Drugs Increased risk of QTc interval prolongation and Torsade de Pointes.

Metabolic and Exposure Alteration

Ondansetron is metabolized by hepatic cytochrome P450 enzymes (CYP3A4, CYP2D6, CYP1A2). This pharmacokinetic profile defines several interactions:

Interacting Substance Interaction Type Formal Outcome
CYP3A4 Inducers (Phenytoin, Carbamazepine, Rifampin) Pharmacokinetic (Increased Clearance) Significantly increased clearance and decreased Ondansetron blood concentrations.
Tramadol Pharmacodynamic (Efficacy Reduction) May result in reduced analgesic activity.

Population-Specific Notes

The presence of severe hepatic impairment is a critical factor, as regulatory documents state that clearance of Ondansetron is substantially decreased and half-life is prolonged in this population. No mandatory time-separation rules for co-administered medicines are specified in the official regulatory documentation. The interaction profile is defined by a primary contraindication and additive pharmacodynamic risks.

Mechanism of Action

Odatron is a fully human monoclonal antibody that targets the Receptor Activator of Nuclear Factor kappa-B Ligand (RANKL). Odatron binds with high specificity to RANKL, acting as an inhibitor to prevent the molecule from engaging its corresponding receptor, RANK.

RANK is expressed on the surface of osteoclast precursor cells and mature osteoclasts. The resulting inhibition of the RANKL-RANK interaction interrupts the crucial signaling pathway required for osteoclast formation, function, and survival. This interruption leads to a decrease in osteoclast-mediated bone resorption.

The RANKL pathway modulation consequentially shifts the equilibrium of bone remodeling toward reduced bone turnover. This mechanistic effect is realized through Odatron's extracellular binding to its target, thereby modifying cellular processes within the skeletal system.

Dosage and Administration Information

Official Administration Guidelines for Odatron (Ondansetron)

Odatron is administered via oral (tablets, orally disintegrating tablets [ODT], or solution) and parenteral (intravenous or intramuscular) routes. Its use follows standardized, event-specific dosing regimens. The treatment is primarily designed for short-term prophylaxis, with doses given prior to and for a limited period after an emetogenic event.


Standard Labeled Dosing Regimens (Adults)

Context Initial Dosing Follow-up Dosing (Oral)
Highly Emetogenic Chemotherapy (HEC) Single 24 mg oral dose (30 minutes before treatment). No routine follow-up dose specified in this regimen.
Moderately Emetogenic Chemotherapy (MEC) 8 mg oral dose (30 minutes before treatment), followed by 8 mg 8 hours later. 8 mg every 12 hours for 1 to 2 days after chemotherapy completion.
Postoperative Nausea & Vomiting (PONV) Single oral dose of 16 mg (1 hour before anesthesia) or single 4 mg IV/IM dose (at induction or postoperatively). No routine follow-up for prophylaxis.

Specific Use and Administration Instructions

Administration Timing and Conditions: Oral tablets can be taken with or without food. Orally Disintegrating Tablets (ODTs) must be handled with dry hands and placed directly on the tongue to dissolve. High-dose IV infusions must be diluted in 5% Dextrose or 0.9% Sodium Chloride and infused over 15 minutes. Low-dose IV boluses (e.g., 4 mg) should be administered over at least 30 seconds.

Population-Specific Rule: For patients diagnosed with severe hepatic impairment (Child-Pugh score ≥ 10), the total daily dose from all routes must not exceed 8 mg. No routine dosage adjustment is specified for older adults or patients with renal impairment.

Recent Clinical Evidence

Odatron: Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Component A

Clinical research on Component A has been explored as a potential therapeutic option for chronic inflammatory conditions. Studies examined the effects of Component A on biological markers. Findings indicated an association with a change in inflammation markers across multiple research models. Furthermore, research focused on evaluating the results on markers of immune function.

Research on Component B

Studies have assessed Component B primarily for its effect on cellular regulation and tissue repair. Research has explored whether the combination produced different observations related to symptoms compared to the individual components. The compound was evaluated in participants experiencing flare-ups.

Combined Therapy Studies

Joint Health Outcomes

In a pilot study, researchers assessed the effect on musculoskeletal outcomes. Specifically, studies assessed whether there were changes in joint mobility measures over a 12-week period. Furthermore, studies explored a link with observations of pain severity ratings as reported by participants.

Safety and Tolerability

Long-term data collection for safety was performed in the study participants. Tolerability was recorded and reported by study participants.

Frequently Asked Questions (FAQ)

Common questions about Odatron (FAQ)


Q: How quickly does Odatron start to have an effect?

Studies on Odatron's pharmacokinetics show that after taking the medicine orally, the highest concentration in the bloodstream is typically reached in approximately 1.5 to 3 hours. This indicates that the drug's concentration is at its peak in the body within this timeframe. Official dosing instructions usually require the medicine to be administered shortly before the event that causes sickness (such as chemotherapy or surgery) to ensure it is available when needed.


Q: Can Odatron be taken with common over-the-counter pain relievers?

The official product information primarily focuses on interactions with certain heart medicines (QT-prolonging drugs) or drugs that affect serotonin levels. While commonly used over-the-counter pain relievers, such as acetaminophen or ibuprofen, are not generally listed as having a major formal interaction, information about all medicines and products should be shared with a healthcare provider.


Q: Can Odatron be stopped suddenly, or does it need to be tapered?

Odatron is typically described in official documents for short-term use to prevent sickness following specific medical events. The recommended follow-up dosing is for a limited duration, often just a few days. This profile indicates that for its labeled uses, the medicine is not typically associated with withdrawal effects requiring tapering.


Q: Does Odatron affect birth control pills?

Based on studies of drug-drug interactions, Odatron is not generally shown to have a significant effect on the concentrations of hormonal ingredients in common birth control pills (estrogens or progestins). It is worth noting that any episode of severe sickness or vomiting can potentially affect the absorption of oral contraceptives.


Q: What happens if Odatron is taken with alcohol?

Regulatory documents do not list a major formal interaction specifically with alcohol (ethanol). However, consuming alcohol may potentially make some of the common reported adverse reactions of Odatron, such as headache or tiredness, more noticeable. It may also worsen the underlying condition or symptoms that Odatron is being used to treat.


Q: Is Odatron safe during pregnancy or breastfeeding?

According to official product information, the use of Odatron during pregnancy is generally not recommended, especially during the first trimester. Furthermore, it is not recommended to breastfeed while undergoing treatment, as the drug and its related substances are known to be excreted into animal milk.


Q: How does Odatron help with the underlying condition it treats?

Odatron is an anti-sickness medicine that works by blocking key chemical signals—specifically serotonin—in both the gut and the area of the brain that controls the vomiting reflex. By intercepting these signals, the medicine is intended to prevent and relieve the sensation of sickness that can follow medical procedures like chemotherapy, radiation, or surgery.


Q: Can Odatron be crushed or split if it's a pill?

Official administration instructions specify that the Orally Disintegrating Tablets (ODTs) are designed to dissolve on the tongue. Standard oral tablets are generally intended to be taken whole to ensure the correct amount of medicine is delivered and functions as expected. Altering the tablet form, such as crushing or splitting, may affect the intended absorption and function.


Q: What should I do if I miss a dose of Odatron?

If a dose is missed, regulatory information generally advises that it should be taken as soon as it is remembered. If the time is near the next scheduled dose, the missed dose should be skipped, and patients are generally advised to continue with the regular dosing schedule. It is specified that two doses should not be taken to make up for a missed one.


Q: Can Odatron cause long-term side effects?

Odatron is prescribed for short-term preventative use. Official safety data primarily describes effects observed during and shortly after administration. While serious adverse reactions like QT prolongation (a heart rhythm concern) are possible, regulatory documents do not specify long-term effects beyond the period when the medication is being used.


Q: Is it normal to feel tired when taking Odatron?

The official regulatory adverse reaction lists do include reports of general symptoms such as malaise or fatigue (tiredness) in some patients during clinical studies. While not listed among the 'very common' effects, it is listed as a possible reported reaction.


Q: Does Odatron affect alertness or driving ability?

Official documents state that Odatron has not been shown to impair the ability to drive or operate machinery. However, reported effects like dizziness and transient visual disturbances (temporary vision changes) could temporarily impact attention and the ability to drive or use complex equipment.


Q: Is Odatron a controlled substance or addictive?

Odatron is classified as a prescription-only (Rx-only) medicine in major global jurisdictions. It is not currently designated or listed as a scheduled controlled substance, indicating it does not carry the same risk of abuse or dependence as controlled substances.


Q: What happens if I'm taking herbal supplements with Odatron?

Odatron is processed in the body by certain liver enzymes, known as CYP450 enzymes. Some herbal supplements are known to affect these same enzymes. Therefore, a supplement could potentially change the concentration of Odatron in the blood. All supplements should be reviewed with a healthcare provider.


Q: Are there specific times of day Odatron is usually recommended?

Odatron administration is generally tied to a specific medical event. For example, it is typically recommended to be taken 30 minutes before the start of chemotherapy or 1 hour before anesthesia. The timing is designed to ensure the drug is active in the body precisely when the risk of sickness is highest.


Q: Is it possible to take too much Odatron?

Yes, taking doses higher than recommended is considered an overdose. Regulatory documents report that effects observed in overdose have included low blood pressure (hypotension) and heart rhythm changes, as well as temporary vision changes or symptoms of Serotonin Syndrome (a serious side effect associated with high serotonin levels).


Q: Are there any genetic factors that might affect how Odatron works?

Odatron is broken down by several liver enzymes, including CYP2D6. Genetic variations can change the activity of this enzyme in an individual. Official documents note that this genetic factor may alter the drug’s concentration in the body. This information may be considered by healthcare providers.


Q: How long does Odatron stay in the body after the last use?

The drug's elimination half-life, which is the time it takes for half of the dose to be cleared from the body, is approximately 3 to 6 hours for adults. This half-life helps to describe the drug's persistence in the body and its duration of action.


Q: Can Odatron cause changes in mood or sleep patterns?

Reports collected during clinical trials and post-marketing surveillance have documented less common effects involving the nervous system and mental health. These adverse reactions have included reports of anxiety/agitation and sleep disturbances (such as insomnia or excessive sleepiness).


Q: What should be discussed with a healthcare provider before starting Odatron?

Official information indicates that discussion points should include all current medications, especially those that can affect heart rhythm or are known as serotonergic drugs (like certain antidepressants). Any history of a specific heart condition called Long QT Syndrome or problems with body salts (uncorrected electrolyte abnormalities) are also important discussion points.

How should Odatron be stored and disposed of?

How to Store and Dispose of Odatron (Ondansetron)

Odatron must be stored at Controlled Room Temperature (typically 20 C to 25 C) and kept protected from both light and moisture. The injectable solution should not be frozen. Orally Disintegrating Tablets (ODTs) must remain in their original protective package until the moment of use.

Stability and Child Safety

Once the injection solution is diluted, it must be used within 24 hours due to microbiological considerations. Like all medicines, Odatron must be stored out of the sight and reach of children.

Disposal

Any unused or expired product must be disposed of in accordance with local requirements. Odatron is not on the list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Odatron found in:

A-Z Index: